Member Info for Borsaci06

Jack
the issue is not ACE2, it is TMPRSS2 enzyme which helps virus enter cell

Fake news has been circulating on social media that the first volunteer in the Oxford vaccine trial has died
https://twitter.com/BBCFergusWalsh/status/1254356432780214272

more ACE2 production is not problem for German scientists. This is how they do;

" Enhanced isolation of SARS-CoV-2 by TMPRSS2-
expressing cells "
https://www.pnas.org/content/pnas/early/2020/03/11/2002589117.full.pdf

https://twitter.com/ARanganathan72/status/1239269804445331456?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1239269804445331456&ref_url=https%3A%2F%2Fwww.redditmedia.com%2Fmediaembed%2Ffjpc2e%3Fresponsive%3Dtrue%26is_nightmode%3Dfalse

" Biologists at the German Primate Centre in Göttingen found that SARS-CoV-2 depends on TMPRSS2 protease to invade cells and more importantly from a therapeutic perspective, showed that a protease inhibitor previously approved for clinical use, camostat mesylate, can block the virus from entering cells. "
https://www.forbes.com/sites/jvchamary/2020/04/17/coronavirus-spike-protein/#7f039ed32b27

have read the analogy in this article

" The TMPRSS2 is required to initiate the expression of the spike (S) protein, which is key to the entry of the virus and its spread between hosts "
https://www.news-medical.net/news/20200420/ACE2-TMPRSS2-profiling-indicates-tissue-vulnerability-to-SARS-CoV-2-infection.aspx

" The TMPRSS2 is required to initiate the expression of the spike (S) protein, which is key to the entry of the virus and its spread between hosts "
https://www.news-medical.net/news/20200420/ACE2-TMPRSS2-profiling-indicates-tissue-vulnerability-to-SARS-CoV-2-infection.aspx

think, the issue is not ACE2 but is the TMPRSS2 enzyme

" sars-cov2 S protein priming by TMPRSS2 is essential for viral entry into primary target cells and for viral spread in the infected host "
https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1.full.pdf

" SARS-CoV-2 docks onto cells with ACE2 receptors with the help of an enzyme known as TMPRSS2. This enzyme slices the spike protein of the virus to activate it and allow the virus to enter the cell "
https://www.livescience.com/coronavirus-immune-interferon-response.html

people using ACE2 inhibitors still get infected with sars-cov2

this is from asthma.org.uk

" Bear in mind that your reliever inhaler helps with symptoms like breathlessness, coughing or chest tightness that are caused by asthma, and may not help these symptoms if caused by COVID-19. This is because both asthma and COVID-19 can cause similar symptoms but for a different reason, and your inhaler only works against symptoms caused by asthma "

https://www.asthma.org.uk/advice/triggers/coronavirus-covid-19/covid-19-and-asthma/#GettingSymptoms

?? think, he had something else in nebuliser

it is been going on in France ,
using solution not in form of inhaler

https://clinicaltrials.gov/ct2/show/NCT04315948?id=NCT04251871+OR+NCT04276688+OR+NCT04315948+OR+NCT04320238+OR+NCT04293887+OR+NCT04275388&draw=2&rank=2&load=cart

Actual Study Start Date : March 22, 2020
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

WHO Solidarity” clinical trial for COVID-19 treatments

Drug: Interferon Beta-1A
IFN-ß-1a is supplied as a STERILE SOLUTION containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe

* Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered every 12 h for 14 days in tablet form. For patients who are unable to take medications by mouth, the lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir) will be administered as a 5-ml suspension every 12 h for 14 days via a pre-existing or newly placed nasogastric tube.

* Interferon ß1a will be administered subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6).
n=620

" Trial of chloroquine to treat COVID-19 stopped early due to heart complications
In the Brazilian study, some patients taking a high dose of the drug developed dangerous heart rhythm problems. "
https://www.livescience.com/coronavirus-chloroquine-study-stopped-early.html

RNS Number : 5374G
Synairgen plc
18 March 2020
SNG001 was identified in the WHO's Landscape analysis of therapeutics as at 17 February 2020 as the only Phase 2/Phase 3/Observational therapy delivered by the inhaled route

https://www.who.int/blueprint/priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf?ua=1

https://www.youtube.com/watch?v=61WdX-_Jjmw published on Jan 7, 2013FDA approval Feb, 2020

anyone received alleged " email, screenshot, whatsapp " post them here as well as contacts/requests from nomad/company

we all WANT COPY of alleged; email, screenshot, whatsapp message etc.. out on this board